Alpha Tau Medical treats first patient in US pancreatic cancer trial
Ticker: DRTSW · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, medical-technology, oncology
TL;DR
Alpha Tau just treated the first patient in their US pancreatic cancer trial. Big step for their DLA tech!
AI Summary
Alpha Tau Medical Ltd. announced on September 2, 2025, that it has successfully treated the first patient in its U.S. multi-center clinical trial for pancreatic cancer. This milestone marks a significant step in the company's efforts to develop its Diffuse Laser Ablation (DLA) technology for treating this challenging disease.
Why It Matters
This event is a crucial step in validating Alpha Tau's DLA technology for pancreatic cancer, a notoriously difficult-to-treat malignancy, potentially offering a new therapeutic option.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with success not guaranteed, and regulatory approvals are still pending.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — The company filing the report and conducting the trial.
- September 2, 2025 (date) — Date of the press release and filing.
- U.S. (location) — Location of the multi-center clinical trial.
- pancreatic cancer (disease) — The disease being targeted in the clinical trial.
FAQ
What is the specific technology Alpha Tau Medical is using in this trial?
Alpha Tau Medical is using its Diffuse Laser Ablation (DLA) technology.
Where is the multi-center clinical trial for pancreatic cancer being conducted?
The trial is being conducted in the U.S.
What is the significance of treating the first patient in this trial?
Treating the first patient signifies the commencement of patient treatment within the trial and a step towards evaluating the efficacy and safety of the DLA technology for pancreatic cancer.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed with the SEC, which includes a press release as Exhibit 99.1.
When was the press release announcing this milestone issued?
The press release was issued on September 2, 2025.
Filing Stats: 303 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-09-02 08:30:59
Filing Documents
- ea0255422-6k_alpha.htm (6-K) — 14KB
- ea025542201ex99-1_alpha.htm (EX-99.1) — 17KB
- 0001213900-25-082941.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: September 2, 2025 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3